2026年8月,FDA批准第二款溶瘤病毒疗法Tudriqev,用于PD-1耐药的晚期黑色素瘤。改造疱疹病毒注射入肿瘤后溶瘤释放抗原,激活免疫系统并联合O药,24.2%患者肿瘤缩小,中位缓解持续14.1个月,为无药可用患者带来新希望。
参考文献:
FDA. FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma. 2026-08-06. www.fda.gov
FDA. FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma. 2026-08-06. www.fda.gov
Replimune. IGNYTE Trial Presentation, FDA CTGTAC Meeting. 2026-07-30. ir.replimune.com
Replimune. 3-Year Landmark OS Analysis from IGNYTE, ASCO 2026. ir.replimune.com
IGNYTE Trial (NCT03767348), RP1 + Nivolumab in Advanced Anti-PD-1-Failed Melanoma. PMC. pmc.ncbi.nlm.nih.gov

